Covid 19: SCOPE: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adults Aged 18 Years and Older

Grants and Contracts Details

StatusActive
Effective start/end date9/25/206/7/23

Funding

  • Janssen Vaccines and Prevention BV